Joseph Jaros is a partner at Rakoczy Molino Mazzochi Siwik LLP. Mr. Jaros has almost twenty years of complex litigation experience, including ten years managing Hatch-Waxman litigation matters exclusively.
Mr. Jaros manages Hatch-Waxman cases involving a range of claimed pharmaceutical technologies, including new chemical entities, polymorphs, drug delivery devices, formulations, and methods of treatment.
Representative matters involved mometasone (Nasonex), aripiprazole (Abilify), bimatoprost (Latisse), albuterol (ProAir), tiagabine (Gabitril), valganciclovir (Valcyte), ranolazine (Ranexa), capecitabine (Xeloda), doxycycline (Oracea), colesevelam (Welchol), atorvastatin (Lipitor), eszopiclone (Lunesta), fenofibrate (Antara), fenofibrate (Tricor), doxepin (Silenor), ketorolac (Acular), quetiapine (Seroquel), brimonidine/timolol (Combigan), rosuvastatin (Crestor), lamivudine/zidovudine (Combivir), tramadol (ConZip), omega-3 (Lovaza), norethindrone/ethinyl estradiol (Femcon), amlodipine/benazepril (Lotrel), and divalproex (Depakote).
Intellectual Property and Complex Commercial Litigation
Earlier in his career, Mr. Jaros represented clients in a variety of litigation matters, including patent infringement, trademark infringement, copyright infringement, trade secret misappropriation, unfair competition, breach of contract, mass tort and class actions. In addition, Mr. Jaros was lead counsel in a federal civil rights jury trial and second-chaired a breach of contract jury trial.
Previous Law Firm Experience
Before joining RMMS, Mr. Jaros was an associate at Kirkland & Ellis LLP and Holland & Hart LLP.
Northwestern University School of Law
University of Chicago
(B.A., 1993; Phi Beta Kappa)
Federal Circuit Court of Appeals
American Bar Association
- Federal Circuit Affirms Collateral Estoppel Decision Concerning Latisse® (bimatoprost topical solution) March 17, 2017
- RMMS Secures Favorable Claim Construction Ruling In Suit Involving Generic Aripiprazole (Abilify®) November 16, 2015
- Chief Judge Simandle Allows Launch of Generic Aripiprazole (Abilify®) April 16, 2015
- RMMS Defeats Motion for Preliminary Injunction Involving Generic Tiagabine Hydrochloride Products December 20, 2012